Literature DB >> 28003220

Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a).

Monika Sharma1, Gregory M Redpath1, Michael J A Williams1, Sally P A McCormick2.   

Abstract

RATIONALE: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like lipoprotein and important cardiovascular risk factor whose cognate receptor and intracellular fate remains unknown.
OBJECTIVE: Our study aimed to determine the intracellular trafficking pathway for Lp(a) and the receptor responsible for its uptake in liver cells. METHODS AND
RESULTS: Human hepatoma cells were treated with Lp(a) purified from human plasma and Lp(a) uptake studied using Western blot analysis and intracellular localization of Lp(a) by confocal microscopy. Lp(a) was maximally internalized by 2 hours and was detected by an antiapo(a) antibody to be localized to Rab5-positive early endosomes, the trans-Golgi network, and subsequently Rab11-positive recycling endosomes. In human hepatoma cells, the apo(a) component from the internalized Lp(a) was resecreted back into the cellular media, whereas the low-density lipoprotein component was localized to the lysosomal compartment. Lp(a) internalization was reduced 0.35-fold in HAP1 and 0.33-fold in human hepatoma cells in which the plasminogen receptor (KT) was knocked out. Conversely, Lp(a) internalization was enhanced 2-fold in HAP1 and 1.6-fold in human hepatoma cells in which plasminogen receptor (KT) was overexpressed, showing for the first time the role of a specific plasminogen receptor in Lp(a) uptake.
CONCLUSIONS: The novel findings that Lp(a) is internalized by the plasminogen receptor, plasminogen receptor (KT), and the apo(a) component is recycled may have important implications for the catabolism and function of Lp(a).
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  lipoprotein(a); liver; plasminogen receptor; recycling endosomes

Mesh:

Substances:

Year:  2016        PMID: 28003220     DOI: 10.1161/CIRCRESAHA.116.310272

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  16 in total

Review 1.  Functions of the plasminogen receptor Plg-RKT.

Authors:  Lindsey A Miles; Juliana P Vago; Lirlândia P Sousa; Robert J Parmer
Journal:  J Thromb Haemost       Date:  2020-08-19       Impact factor: 5.824

Review 2.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

3.  Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.

Authors:  Aurélie Thedrez; Dirk J Blom; Stéphane Ramin-Mangata; Valentin Blanchard; Mikaël Croyal; Kévin Chemello; Brice Nativel; Matthieu Pichelin; Bertrand Cariou; Steeve Bourane; Lihua Tang; Michel Farnier; Frederick J Raal; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-12-28       Impact factor: 8.311

Review 4.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

5.  Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Authors:  Justin R Clark; Matthew Gemin; Amer Youssef; Santica M Marcovina; Annik Prat; Nabil G Seidah; Robert A Hegele; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2022-04-22       Impact factor: 6.676

6.  Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgRKT to the List.

Authors:  Calvin Yeang; Philip L S M Gordts; Sotirios Tsimikas
Journal:  Circ Res       Date:  2017-03-31       Impact factor: 23.213

7.  Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab.

Authors:  Kévin Chemello; Sandra Beeské; Thi Thu Trang Tran; Valentin Blanchard; Elise F Villard; Bruno Poirier; Jean-Christophe Le Bail; Gihad Dargazanli; Sophie Ho-Van-Guimbal; Denis Boulay; Olivier Bergis; Marie-Pierre Pruniaux; Mikaël Croyal; Philip Janiak; Etienne Guillot; Gilles Lambert
Journal:  JACC Basic Transl Sci       Date:  2020-05-06

Review 8.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

9.  CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.

Authors:  Tiffany Thomas; Haihong Zhou; Wahida Karmally; Rajasekhar Ramakrishnan; Stephen Holleran; Yang Liu; Patricia Jumes; John A Wagner; Brian Hubbard; Stephen F Previs; Thomas Roddy; Amy O Johnson-Levonas; David E Gutstein; Santica M Marcovina; Daniel J Rader; Henry N Ginsberg; John S Millar; Gissette Reyes-Soffer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

10.  Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).

Authors:  Xiang Zhang; Lotte C A Stiekema; Erik S G Stroes; Albert K Groen
Journal:  Lipids Health Dis       Date:  2020-05-11       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.